Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Hyperlipidaemia in chronic kidney disease.

C M Chan1

  • 1Department of Renal Medicine, Singapore General Hospital, Singapore. grmccm@sgh.com.sg

Annals of the Academy of Medicine, Singapore
|February 24, 2005
PubMed
Summary

Patients with chronic kidney disease (CKD) have high rates of dyslipidaemia, increasing cardiovascular disease risk. Aggressive LDL cholesterol management is crucial for these high-risk individuals.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pediatric head and neck manifestations associated with multiple endocrine neoplasia syndromes.

International journal of pediatric otorhinolaryngology·2023
Same author

Corrigendum to "Examination of seroprevalence of coronavirus HKU1 infection with S protein-based ELISA and neutralization assay against viral spike pseudotyped virus" Journal of Clinical Virology 45 (2009) 54-60.

Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology·2022
Same author

Phase I dose escalating study of oral cyclophosphamide in tumour-bearing cats.

Veterinary journal (London, England : 1997)·2020
Same author

Dosage escalation of intravenous cyclophosphamide in cats with cancer.

Veterinary journal (London, England : 1997)·2018
Same author

Intravoxel incoherent motion and diffusion tensor imaging of early renal fibrosis induced in a murine model of streptozotocin induced diabetes.

Magnetic resonance imaging·2017
Same author

A literature review of reports of the stability and storage of common injectable chemotherapy agents used in veterinary patients.

Veterinary and comparative oncology·2016

Area of Science:

  • Nephrology
  • Cardiology
  • Clinical Lipidology

Background:

  • Cardiovascular disease (CVD) is a leading cause of death in chronic kidney disease (CKD) patients.
  • Dyslipidaemia, particularly elevated low-density lipoprotein (LDL) cholesterol, is significantly more prevalent in CKD patients than the general population.
  • Most CKD patients die from CVD before progressing to end-stage renal disease.

Purpose of the Study:

  • To highlight the high prevalence of dyslipidaemia in CKD.
  • To emphasize the critical link between dyslipidaemia and CVD mortality in CKD.
  • To recommend screening and aggressive management of dyslipidaemia in CKD patients.

Main Methods:

  • Evaluation of dyslipidaemia in all CKD patients.
  • Measurement of complete fasting lipid profiles, including total cholesterol, LDL cholesterol, high-density lipoprotein cholesterol, and triglycerides.
  • Application of K/DOQI and NCEP ATP III guidelines for risk stratification and treatment.

Main Results:

  • CKD patients exhibit significantly higher levels of total and LDL cholesterol.
  • Dyslipidaemia is a major contributor to the elevated CVD risk in this population.
  • CKD patients are classified as a "very high risk" category for cardiovascular events.

Conclusions:

  • All patients with CKD require evaluation for dyslipidaemia.
  • Aggressive therapeutic intervention targeting LDL cholesterol is essential to mitigate cardiovascular risk in CKD.
  • Management strategies should align with established guidelines for high-risk individuals.

Related Experiment Videos